2009
Cannabis and psychosis/schizophrenia: human studies
D’Souza D, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. European Archives Of Psychiatry And Clinical Neuroscience 2009, 259: 413-431. PMID: 19609589, PMCID: PMC2864503, DOI: 10.1007/s00406-009-0024-2.Peer-Reviewed Original ResearchConceptsPsychotic disordersRole of cannabinoidsPsychosis/schizophreniaTransient psychotic symptomsComponent causesCannabinoid receptor functionCauses of schizophreniaWarrants further studyDuration of exposureCannabinoid exposureTrigger relapsePsychotic illnessPsychotic symptomsGeneral populationCognitive symptomsHealthy individualsHuman studiesReceptor functionCannabis useNeurodevelopmental processesCannabinoidsFirst exposureSymptomsDisordersGenetic factors
2005
Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine
Cho HS, D’Souza D, Gueorguieva R, Perry EB, Madonick S, Karper LP, Abi-Dargham A, Belger A, Abi-Saab W, Lipschitz D, Bennet A, Seibyl JP, Krystal JH. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology 2005, 179: 136-143. PMID: 15682309, DOI: 10.1007/s00213-004-2066-5.Peer-Reviewed Original ResearchConceptsHealthy human subjectsBehavioral sensitizationReceptor antagonistN-methyl-D-aspartate (NMDA) glutamate receptor antagonistBehavioral effectsHuman subjectsGlutamate receptor antagonistsNMDA receptor antagonistConclusionsThe current dataEvidence of sensitizationRetrospective studyKetamine administrationOutcome measuresNegative symptomsObjectivesThe purposePrevious exposureFirst exposureKetamineSensitizationAntagonistExposurePerceptual alterationsCurrent dataSeparate studiesSubjects